HIV Type 1 Envelope Sequence Diversity in Inner City Community

Slobod, Karen S.; Rencher, Samantha D.; Farmer, Alicia; Smith, F.S.; Hurwitz, Julia L.

doi:10.1089/aid.1994.10.873

Cited by 14 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cells activated by consensus sequences may therefore fail to recognize natural variants of HIV. Others investigators have advocated the use of cocktails to encompass the natural diversity of CD8+ T-cell (and other) epitopes in one vaccine [88][89][90][91].…”

Section: Tackling Hiv Diversitymentioning

confidence: 99%

CD8+ T-cells: Are They Sufficient to Prevent, Contain or Eradicate HIV-1 Infection?

Brown

Hurwitz²,

Zhan³

et al. 2005

CDTID

View full text Add to dashboard Cite

The prevention of HIV-1 by vaccination has proven to be a formidable task. In an ongoing endeavor to end the HIV-1 pandemic, scientists seek vaccines that will elicit quantitatively and qualitatively robust B-cell and T-cell activities. Given that cytotoxic T-lymphocytes (CTL) play a substantial role in the immunological control of immunodeficiency virus infections, this review will focus on vaccines designed to elicit HIV-1-specific CTL. Vaccine approaches using various HIV-1 proteins or specific CTL determinants, partnered with diverse delivery systems and adjuvants will be discussed. Lessons from studies with other virus models (e.g. gamma herpes virus and influenza virus) will also be examined. Since CTL contribute to the success of vaccines in other model systems, an understanding of the strengths and possible limitations of these cells may be critical to future successes in the HIV-1 vaccine field.

show abstract

Section: Tackling Hiv Diversitymentioning

confidence: 99%

CD8+ T-cells: Are They Sufficient to Prevent, Contain or Eradicate HIV-1 Infection?

Brown

Hurwitz²,

Zhan³

et al. 2005

CDTID

View full text Add to dashboard Cite

show abstract

Subcutaneous Administration of a Recombinant Vaccinia Virus Vaccine Expressing Multiple Envelopes of HIV-1

Slobod

Lockey

Howlett

et al. 2004

European Journal of Clinical Microbiology & Infectious Dise

View full text Add to dashboard Cite

A critical goal of HIV vaccine development is the identification of safe and immunogenic vectors. Recombinant vaccinia virus is a highly effective vaccine vector, with demonstrated capacity to protect animals from various viral pathogens, including rabies. Unlike many other candidate vaccine vectors, vast human experience exists with the parenteral smallpox vaccine. However, consideration of recombinant vaccinia virus as a modern vaccine is complicated by the relatively high prevalence of immunocompromised persons compared to such prevalence 4 or more decades ago (when smallpox vaccination was still routine). Administering vaccine by the subcutaneous (SQ) route, rather than the traditional scarification route, could address these concerns. SQ administration could prevent transmission of vaccinia virus to potentially vulnerable persons; it could also avoid the most common adverse events, which are cutaneous in nature. However, previous studies suggest that elicitation of immune response against passenger gene products following SQ administration requires development of a superficial pox lesion, defeating the intention of SQ administration. This is the first report to demonstrate that SQ administration of recombinant vaccinia virus does elicit immune response to the passenger protein in the absence of a cutaneous pox lesion. Results further show that a multi-envelope HIV vaccine can elicit antibody responses toward heterologous HIV-1 not represented by primary sequence in the vaccine. These findings have global implications because they support the consideration of recombinant vaccinia virus as a valuable HIV vaccine vector system.

show abstract

Preparation and use of vaccinia virus vectors for HIV protein expression and immunization

Ryan¹,

Owens²,

Hurwitz³

1996

Immunology Methods Manual

View full text Add to dashboard Cite

HIV Type 1 Envelope Sequence Diversity in Inner City Community

Cited by 14 publications

References 1 publication

CD8+ T-cells: Are They Sufficient to Prevent, Contain or Eradicate HIV-1 Infection?

CD8+ T-cells: Are They Sufficient to Prevent, Contain or Eradicate HIV-1 Infection?

Subcutaneous Administration of a Recombinant Vaccinia Virus Vaccine Expressing Multiple Envelopes of HIV-1

Preparation and use of vaccinia virus vectors for HIV protein expression and immunization

Contact Info

Product

Resources

About